Doctor Explains How Drugmakers Can Bypass Trump's Drug Price Reduction Order

Trump's Executive Order on Drug Prices

• 🎯 President Trump signed an executive order aimed at lowering prescription drug costs in the U.S. by targeting "unreasonable or discriminatory" practices by foreign countries.
• 💡 The order proposes a "most favored nation" rule, requiring drugmakers to offer U.S. patients the lowest price paid by any comparable developed country.
• 📈 U.S. drug prices are nearly three times higher than in other developed nations, with per capita spending on retail drugs increasing significantly since 1960.

Legal Authority and Challenges

• ⚖️ A former health policy advisor questions President Trump's legal authority to implement such an order, citing previous court rejections due to improper process.
• ⚠️ Drug companies may find ways to circumvent the order, such as getting new drugs approved in the U.S. before they are approved elsewhere, allowing them to set higher prices.
• 🏦 The U.S. market is crucial for pharmaceutical companies, making them resistant to significant price reductions.

Potential Strategies and Criticisms

• 🗣️ The FDA commissioner suggests that the administration is using the full power of the executive branch, including the FTC and DOJ, to address collusion and unfair pricing practices.
• 🏥 The FDA has rulemaking abilities, particularly concerning Medicare, which could be explored to lower drug prices.
• 📉 Critics from the right argue the order resembles Soviet-style price controls, while some economists fear it could lead to U.S. drug prices being set by less developed nations, potentially impacting R&D.

Addressing Drug Affordability

• 💰 The current system results in Americans paying the highest prices, with disparities between Medicaid, VA, and commercially insured individuals.
• 💔 High drug prices contribute to financial toxicity, medical bankruptcy, and reliance on crowdfunding for essential medications.
• 🤝 The FDA aims to work with pharmaceutical companies and middlemen to negotiate lower prices, emphasizing that the U.S. is seeking fair pricing comparable to other wealthy nations.